Corey Davis
Stock Analyst at HC Wainwright & Co.
(2.94)
# 1,396
Out of 5,152 analysts
17
Total ratings
75%
Success rate
25.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corey Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterates: Neutral | $480 → $390 | $72.45 | +438.30% | 5 | May 12, 2020 | |
| SCYX SCYNEXIS | Assumes: Buy | $50 | $0.79 | +6,209.15% | 3 | May 7, 2018 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | $560 → $40 | $37.22 | +7.47% | 2 | Apr 10, 2018 | |
| LPCN Lipocine | Initiates: Buy | $170 | $8.19 | +1,975.70% | 1 | Mar 29, 2018 | |
| VNDA Vanda Pharmaceuticals | Initiates: Buy | $20 | $7.91 | +152.84% | 2 | Jan 19, 2018 | |
| PCRX Pacira BioSciences | Initiates: Buy | $50 | $22.86 | +118.72% | 3 | Jan 19, 2018 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Neutral | $144 | $183.63 | -21.58% | 1 | Aug 25, 2017 |
Nektar Therapeutics
May 12, 2020
Reiterates: Neutral
Price Target: $480 → $390
Current: $72.45
Upside: +438.30%
SCYNEXIS
May 7, 2018
Assumes: Buy
Price Target: $50
Current: $0.79
Upside: +6,209.15%
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: $560 → $40
Current: $37.22
Upside: +7.47%
Lipocine
Mar 29, 2018
Initiates: Buy
Price Target: $170
Current: $8.19
Upside: +1,975.70%
Vanda Pharmaceuticals
Jan 19, 2018
Initiates: Buy
Price Target: $20
Current: $7.91
Upside: +152.84%
Pacira BioSciences
Jan 19, 2018
Initiates: Buy
Price Target: $50
Current: $22.86
Upside: +118.72%
Jazz Pharmaceuticals
Aug 25, 2017
Initiates: Neutral
Price Target: $144
Current: $183.63
Upside: -21.58%